Cardiac Science closes Artema purchase:
This article was originally published in Clinica
Executive Summary
Almost 95% of the shareholders of Swedish patent monitor and defibrillator manufacturer Artema Medical had accepted the takeover offer from Cardiac Science by the final application date of November 23. The Irvine, California company was planning to complete the share exchange on November 30, and said its consideration would amount to around four million shares. The company also planned to compulsorily purchase to the outstanding shares and seek a delisting of the Stockholm company's shares. Artema will bring an expanded in-hospital defibrillator line, enhanced distribution in Europe, the Middle East and Asia, and an installed base of some 6,000 patient monitors. CLINICA -World Medical Device & Diagnostic News FILED 27 November 2001 COPYRIGHT 2001 PJB Publications Ltd
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.